Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24460873 | 0.86 | GRIN1 (0.53) | GRIN1GRIN2BMAOBMAOAKCNH2 | |
| SCHEMBL10272647 | 0.82 | MRGPRX4 (0.64) | MRGPRX4CYP1A2LMNAPTGS1SLC6A2 | |
| SCHEMBL21964488 | 0.82 | MRGPRX4 (0.51) | MRGPRX4CYP1A2LMNAPTGS1SLC6A2 | |
| SCHEMBL17468456 | 0.82 | TP53 (0.52) | MRGPRX4CYP1A2LMNAPTGS1SLC6A2 | |
| SCHEMBL8990466 | 0.80 | ESR2 (0.39) | GRIN1GRIN2BCYP2C19MEN1KMT2A | |
| SCHEMBL14336757 | 0.79 | SLC18A3 (0.45) | GRIN2BGAAL3MBTL1 | |
| SCHEMBL19339365 | 0.79 | GRIN1 (0.48) | GRIN1GRIN2BCYP1A2LMNAPTGS1 | |
| SCHEMBL24460870 | 0.78 | HTR1A (0.60) | GRIN1GRIN2BCYP1A2LMNASLC6A2 | |
| SCHEMBL5249481 | 0.78 | HRH3 (0.60) | MRGPRX4CYP1A2LMNAPTGS1SLC6A2 | |
| SCHEMBL16969436 | 0.77 | ESR2 (0.57) | MRGPRX4CYP1A2LMNAPTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-0035902-B1 | 1-(4-ARYL-CYCLOHEXYL)PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-31 | — | — | EP | disclosed |
| US-4329353-A | ANTIEMETIC AND NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | GRIN1 1134/4885GRIN2B 1562/4885MRGPRX4 1196/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | GRIN1 1134/4885GRIN2B 1562/4885MRGPRX4 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.